Albuquerque, NM – August 19, 2020 – BennuBio, Inc. (BennuBio) announced today that its large particle flow cytometer, the Velocyt, has the potential to address one of the most devastating side effects of serious COVID-19 infections: blood clots. By detecting the “seeds” of blood clots—called micro-emboli—early, clinicians can apply targeted treatment strategies. In addition, the instrument’s unique design makes it applicable for rare event detection as well as other challenges in COVID-19 research, such as antibody response, latent virus-infected cells, perturbed immune cell signatures and cytokine storm.

Following the $1M NIH (National Institute of Health) SBIR (Small Business Innovation Research) grant to advance the company’s development of a novel analytic tool for 3D tissue models, BennuBio is now poised to use the Velocyt to support COVID-19 research.  

BennuBio is an Albuquerque, New Mexico-based biotechnology company focused on developing innovative large particle cell analysis instruments for biomedical and pharmaceutical research.